Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity

Go back to Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity
NOVO-NORDISK A/S (NYSE: NVO) Delayed: 39.43 +0.37 (0.95%)
Previous Close $39.06    52 Week High $59.00 
Open $39.39    52 Week Low $32.80 
Day High $39.77    P/E N/A 
Day Low $39.24    EPS $0.00 
Volume 8,556,398